Tony Mauro, president of Mylan North America and its Mylan Pharmaceuticals subsidiary, has been elected as chairman of the Generic Pharmaceutical Association (GPhA) board of directors.


Tony Mauro, Mylan, Generic Pharmaceutical Association, GPhA, chairman, GPhA chairman, Mylan Pharmaceuticals, Ralph Neas, Paul Bisaro, Watson, generic pharmaceutical industry, generic drug, generic drug makers, Don DeGolyer, Sandoz, vice chairman, Craig Wheeler, Momenta Pharmaceuticals, secretary treasurer


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan's Mauro tabbed as GPhA chairman

February 27th, 2012

PITTSBURGH – Tony Mauro, president of Mylan North America and its Mylan Pharmaceuticals subsidiary, has been elected as chairman of the Generic Pharmaceutical Association (GPhA) board of directors.

Mylan said Friday that Mauro's term as GPhA chairman will last for one year. He will take the reins from Watson Pharmaceuticals Inc. president and chief executive officer Paul Bisaro, the previous GPhA chairman.

Mauro formerly was vice chairman at GPhA, serving two one-year terms.

"I would like to thank the GPhA board of directors and membership for this opportunity, and also acknowledge [GPhA president and CEO] Ralph Neas for his strong leadership of GPhA since joining the organization," Mauro said in a statement. "I sincerely look forward to serving as chair and continuing to work closely with the board and Ralph during this truly monumental era in our industry. With growing populations, economic recessions and increasing health care costs, the need for widespread access to more affordable medicine has never been so great. The generic pharmaceutical industry, which accounts for 78% of all prescriptions dispensed in the U.S., has played an important role in saving the U.S. health care system and consumers an estimated $931 billion over the past decade."

In 15 years at Mylan, Mauro has held roles of increasing responsibility across the company's business units, including president of Mylan Pharmaceuticals, chief operating officer of Mylan Pharmaceuticals ULC in Canada, vice president of strategic development for North America and vice president of sales for North America.

"Generic drug makers also have stepped forward to assist the Food and Drug Administration in addressing the industrywide challenges, experienced by both brand and generics companies, caused by the globalization of the drug supply chain and the corresponding increase in the FDA's workload," Mauro added. "This effort positions GPhA at the forefront of our industry's important issues, and advises policy makers that they should look to us as a key partner when tackling current and future challenges."

Other GPhA board members elected were Don DeGolyer, president and CEO of Sandoz Inc., as vice chairman, and Craig Wheeler, president of Momenta Pharmaceuticals Inc., who was re-elected as secretary treasurer.

"We are extremely grateful for the support and leadership of everyone on the 2011 board of directors and look forward to working closely with the new board in the year ahead," Neas stated. "Their leadership will be critical as we move into a new and exciting time for our industry and work to ensure that patients continue to have access to safe and effective generic medicines."

Advertisement